Pfizer-KineMed Collaboration Extends to Target Novel Diabetes Pathways

  Pfizer-KineMedCollaborationExtendstoTargetNovelDiabetes Pathways

Business Wire

EMERYVILLE, Calif. -- March 27, 2013

KineMed Inc. (www.kinemed.com) today announced the renewal of a non-exclusive
research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of
novel approaches towards metabolic disease, in particular Type II Diabetes.
The collaboration will employ KineMed’s unique dynamic proteomics technology
platform to map the impact of potential drug candidates on specific metabolic
pathways.

Diabetes is an emerging global healthcare epidemic with an estimated 347
million people affected, according to the WHO. Diabetes is predicted to become
the seventh leading cause of death in the world by the year 2030 and total
deaths from diabetes are projected to rise by more than 50% in the next 10
years.

In the United States Type II diabetes affects over one quarter of Americans
over the age of 65. Diabetes is a major cause of heart disease and stroke, and
is now also the leading cause of kidney failure, non-traumatic lower-limb
amputations and new cases of blindness among adults.

Despite 50 years of drug research, over 60% of patients remain unresponsive to
current therapies, requiring novel approaches to address fundamental metabolic
processes in diabetes.

“We are very pleased to announce the renewal of this ongoing partnership in an
important area of medicine that affects so many Americans. Powerful discovery
and investigative abilities of novel disease pathways are key strengths of our
translational platform,” said Dr. Scott Turner, Executive Vice-President, R&D
at KineMed. “We look forward to continuing to work with Pfizer to accelerate
and rapidly de-risk the advancement of novel compounds in pre-clinical and
clinical trials.”

About KineMed, Inc.

KineMed has created a broadly enabling proprietary technology that is
potentially transformative in drug development and personalized medicine. Our
Proteome Dynamics and Virtual Biopsy techniques provide a unique marriage of
broad screening capacity (hypothesis-free “-omics” interrogation of living
systems) with functional significance (translational interpretability).
KineMed’s biomarkers are fully translational from animal to man, seamlessly
harmonizing data across pre-clinical and clinical phases of development,
through to the diagnosis and management of diseases including fibrotic,
neurodegenerative, metabolic, cardiovascular disease and cancer.

KineMed has developed the first practically-useful systems biology technology
that can be used directly in humans, with applications not only in drug
discovery and development, but also in clinical diagnosis, personalized
medicine and therapeutic monitoring. Over the past few years our advances in
Proteome Dynamics and Virtual Biopsies have changed both textbook thought
about diseases and the development path of several drug candidates. Notable
accomplishments include:

  *Developing a “tachometer” of reverse cholesterol transport and metrics of
    plasma lipid dynamics
  *Transforming the pathogenic model of chronic lymphocytic leukemia (CLL)
  *Developing the first blood-based biomarker of tissue fibrogenesis in
    humans
  *Generating the first accurate laboratory biomarker of muscle mass in
    humans
  *Creating the first diagnostic tests of disease-modifying processes in a
    neurodegenerative disease (Parkinson’s Disease)

For more information about KineMed, please visit: http://www.kinemed.com

Contact:

KineMed Inc.
Ravi Kiron, Ph.D., MBA, Chief Business Officer
Tel: 510-655-6525 ext. 105
Cell: 650-224-3836
rkiron@kinemed.com
 
Press spacebar to pause and continue. Press esc to stop.